979 Randomized Multicenter Study of Esomeprazole, Moxifloxacin and Amoxicillin for Second-Line or Rescue Treatment of Helicobacter pylori Infection – Impact of Treatment Duration

Berning, Marco; Krasz, Susanne; Schneider-Brachert, Wulf; Madisch, Ahmed; Laaß, Martin W.; Knoth, Holger; Kuhlisch, Eberhard; Neumeyer, Michael; Jebens, Claus; Haferland, Christian; Jacobs, Enno; Stolte, Manfred; Morgner, Andrea; Miehlke, Stephan

doi:10.1016/s0016-5085(09)60677-6

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study from our group showed an overall eradication rate of 78% for the combination of a PPI, moxifloxacin, and rifabutin for 7 days in rescue therapy of H. pylori infection [Miehlke et al 2008]. From a currently ongoing randomized multicenter trial, we have recently reported an eradication rate of 80% and 91% following a 7-day or 14-day treatment, respectively, with esomeprazole, moxifloxacin, and amoxicillin by interim analysis [Berning et al 2009]. …”

Section: Introductionmentioning

confidence: 99%

Should quinolones come first in Helicobacter pylori therapy?

Berning

Krasz

Miehlke

2010

Therap Adv Gastroenterol

Self Cite

View full text Add to dashboard Cite

New generations of fluoroquinolones, like levofloxacin and moxifloxacin, exhibit a broad-spectrum activity against Gram-positive and Gram-negative bacteria, and have been successfully introduced into the treatment of Helicobacter pylori infection. Based on a large body of evidence, current guidelines recommend the use of levofloxacin-or moxifloxacincontaining proton-pump inhibitor (PPI) triple therapies in second-line or rescue treatment of H. pylori infection. The efficacy of standard PPI triple therapies has substantially declined during the last decade, mainly due to increasing resistance against the key antibiotics clarithromycin and metronidazole. Therefore, alternative strategies for first-line therapy of H. pylori infection have been evaluated in a considerable number of clinical trials including sequential regimens, nonbismuth quadruple regimens, and quinolone-containing PPI triple therapy regimens. The aim of this paper is to summarize the current body of evidence of levofloxacin-and moxifloxacin-containing regimens in first-line treatment of H. pylori infection, and to discuss the risks and benefits of these strategies in the light of increasing resistance of H. pylori to quinolones.

show abstract

Section: Introductionmentioning

confidence: 99%

Should quinolones come first in Helicobacter pylori therapy?

Berning

Krasz

Miehlke

2010

Therap Adv Gastroenterol

Self Cite

View full text Add to dashboard Cite

show abstract

“…In einer aktuellen randomisierten Multicenterstudie in Deutschland konnten wir nach 7-tä-giger bzw. 14-tägiger Therapie mit Esomeprazol, Moxifloxacin und Amoxicillin Eradikationsraten von 80% und 91% beobachten [11]. Leider sind deutliche Zunahmen der Fluorochinolon-Resistenzen über die letzten Jahre beobachtet worden.…”

Section: Erstlinientherapieunclassified

Moderne Helicobacter-pylori-Therapien in Zeiten zunehmender Antibiotikaresistenz

Berning¹,

Krasz²,

Labenz

et al. 2010

Med Klin

Self Cite

View full text Add to dashboard Cite

Recommendation for the diagnosis and treatment of Helicobacter pylori Infection are defined in recent national and international guidelines. In Germany, proton pump inhibitor-based triple therapy with clarithromycin and metronidazole or amoxicillin is still the standard in first line therapy. However, success rates have decreased substantially during the last years due to increasing antibiotic resistance, particularly in patients from Southern Europe. In addition, antimicrobial resistance rates against the standard antibiotics further increases dramatically after failure of first line therapy deeming the repeated use of these antibiotics basically impossible. Against this background, a critical appraisal and eventually adaption of therapeutic options both in first line and rescue treatment appears necessary. This paper gives an overview on the current status of therapeutic options and developments in the treatment of H. pylori infection in the light of increasing antibiotic resistance.

show abstract

979 Randomized Multicenter Study of Esomeprazole, Moxifloxacin and Amoxicillin for Second-Line or Rescue Treatment of Helicobacter pylori Infection – Impact of Treatment Duration

Cited by 2 publications

References 0 publications

Should quinolones come first in Helicobacter pylori therapy?

Should quinolones come first in Helicobacter pylori therapy?

Moderne Helicobacter-pylori-Therapien in Zeiten zunehmender Antibiotikaresistenz

Contact Info

Product

Resources

About